hrp0084p2-296 | Diabetes | ESPE2015

Children Born from Mother with Gestational Diabetes Mellitus are at Higher Risk in Metabolic Syndrome

Horikawa Reiko , Arata Naoko , Naiki Yasuhiro

Background: The metabolic outcome in adult life is known to be determined during fetal life. Prenatal poor nutrition also affects growth and maturation, formation of insulin resistance during childhood. Little is known about the effect of maternal gestational diabetes mellitus (GDM) on early metabolic and growth outcome of their children.Objective and hypotheses: To investigate growth, glucose metabolism, and blood pressure in children of mothers with GD...

hrp0098p2-70 | Diabetes and Insulin | ESPE2024

Efficacy of Advanced Hybrid Closed-Loop System Medtronic MiniMed™ 780G in Japanese children with type 1 diabetes mellitus (T1DM)

Ujita Nagisa , Yamada Mihoko , Horikawa Reiko

Background: MiniMed™ 780G was launched in Japan in November 2023 and is expected to further improve glycemic control.Objectives and Methods: 】Subjects of this study were 29 patients with T1DM, aged 2-18 years (average 8.8 years old), who have been treated by SAP using MiniMed™ 770G for at least 3 months prior to switching to 780G smart guard system. We divided subjects into 2 groups by HbA1c levels ove...

hrp0094p2-280 | Growth and syndromes (to include Turner syndrome) | ESPE2021

Outcomes in growth hormone-treated Noonan syndrome children: impact of PTPN11 mutation status

AL Jorge Alexander , Pietropoli Alberto , Kelepouris Nicky , Horikawa Reiko ,

Objectives: Mutations in PTPN11 are known to be associated with Noonan syndrome (NS), accounting for approximately 50% of cases. Data from a non-interventional and phase 3 study of Norditropin (somatropin; Novo Nordisk A/S, Denmark) were used to assess the impact of PTPN11 mutation status on growth outcomes in children with NS receiving growth hormone therapy (GHT).Methods: The ANSWER (NCT01009905) prog...

hrp0097p1-271 | Fat, Metabolism and Obesity | ESPE2023

Investigation of LDL Cholesterol in Children from Seiiku Cohort for Children and Mothers

Doi Hibiki , Yoshii Keisuke , Naiki Yasuhiro , Horikawa Reiko

Background: LDL cholesterol (LDL-C) levels can be high in familial hypercholesterolemia or other dyslipidemia, and the elevated levels are often found in the pediatric setting.Objective: To create a pediatric reference using data of a prospective birth cohort study at our hospital (Seiiku Cohort for Children and Mothers) and to examine its association with possible predisposing factors.Resu...

hrp0097p2-2 | Multisystem Endocrine Disorders | ESPE2023

Genetic test is useful in diagnosing nephrogenic diabetes insipidus.

Ujita Nagisa , Igarashi Mizuho , Yoshii Keisuke , Naiki Yasuhiro , Horikawa Reiko

Background: Congenital nephrogenic diabetes insipidus is a rare disease that is sometimes diagnosed after failure to thrive or febrile illness during infancy. Long-term habitual polydipsia to compensate for polyuria is sometimes difficult to distinguish from habitual polydipsia and polyuria or compulsive drinking.Case: The case is a 10-year-old girl. Her father was diagnosed as having congenital nephrogenic diabetes insi...

hrp0095p1-108 | Growth and Syndromes | ESPE2022

Efficacy, Observer-Reported Outcomes, and Safety of Once-Weekly Somapacitan in Children with Growth Hormone Deficiency (GHD): 4-Year Results from the REAL 3 Trial

Sävendahl Lars , Battelino Tadej , Højby Rasmussen Michael , Brod Meryl , Wai Lee Kai , Saenger Paul , Horikawa Reiko

Children with GHD are currently treated with daily subcutaneous growth hormone (GH) injections, which can be burdensome. Somapacitan is a long-acting GH derivative in development for once-weekly use in children with GHD. REAL 3 (NCT02616562) is a phase 2, multinational, randomised, open label, controlled trial assessing efficacy and safety of somapacitan vs daily GH (Norditropin®). Prepubertal, GH-naïve children with GHD received 0.04 (n=16), 0.08 (n</e...

hrp0095p1-393 | Thyroid | ESPE2022

Urinary Iodine Concentration and Thyroid Function in Children by Age

Igarashi Mizuho , Kashima Takemoto , Hibiki Doi , Yoshii Keisuke , Naiki Yasuhiro , Horikawa Reiko

Background: There are few reports on age-related differences in urinary iodine concentrations, which reflect iodine intake.Objective: We investigated the relationship between age-related differences in urinary iodine concentration and thyroid function.Methods: The subjects were 749 children aged 1 year, 677 children aged 3 years (excluding 2 children aged 3 years whose urinary iodi...

hrp0092p1-406 | Pituitary, Neuroendocrinology and Puberty (2) | ESPE2019

Tolvaptan for Management of Intractable Salt and Water Imbalance in a Case with Suprasellar Tumor after Surgery

Yamaguchi Tomoe , Terashita Shintaro , Kinjo Kenichi , Fujisawa Yusuke , Yoshii Keisuke , Naiki Yasuhiro , Horikawa Reiko

Background: It is sometimes difficult to diagnose and manage fluid and electrolyte imbalance after surgery for hypothalamic/pituitary tumors. We present a pediatric case of severe SIADH successfully treated with tolvaptan after suprasellar tumor resection.Case: The case was 8-year-old girl with growth failure. She was found to have suprasellar tumor on CT scan when she accidentally fell down and hit her head. MRI suggest...

hrp0092lb-1 | Late Breaking Posters | ESPE2019

A Trial Investigating the Long-Term Efficacy and Safety of Two Doses of Norditropin® (Somatropin; Recombinant Human Growth Hormone) in Japanese Children with Short Stature Due to Noonan Syndrome Over Four Years of Treatment

Horikawa Reiko , Ogata Tsutomu , Matsubara Yoichi , Yokoya Susumu , Ogawa Yoshihisa , Nishijima Keiji , Endo Takaaki , Ozono Keiichi

Objectives: This trial (NCT01927861) evaluated the growth-promoting effect and safety of Norditropin® (somatropin; recombinant human growth hormone) in Japanese children with short stature due to Noonan syndrome over four years of treatment.Methods: Pre-pubertal children diagnosed with Noonan syndrome were randomized 1:1 to receive Norditropin® 0.033 mg/kg/day or 0.066 mg/kg/day. Change in...

hrp0089fc10.2 | Late Breaking | ESPE2018

Efficacy and Safety of Once-Weekly Somapacitan in Childhood Growth Hormone Deficiency: Results of a Randomised Open-Label, Controlled Phase 2 Trial

Savendal Lars , Rasmussen Michael , Horikawa Reiko , Khadilkar Vaman , Battelino Tadej , Saenger Paul

Background: Growth hormone deficiency (GHD) requires long-term daily injections with GH replacement therapy and is associated with considerable treatment burden by patients and caregivers. Somapacitan is a long-acting GH derivative that is being developed for once-weekly dosing in adults and children with GHD. A well-established protraction method, which is successfully in use to extend the half-life of insulin and glucagon-like peptide (GLP)-1, has been applied in developing ...